Co-Diagnostics, Inc. Announces Fourth-Quarter and Full-Year 2020 Earnings Release Date and Webcast

Rhea-AI Summary

Co-Diagnostics, Inc. (Nasdaq: CODX) will announce its fourth-quarter and full-year 2020 financial results on March 25, 2021, after market close. The company will host a conference call and webcast at 4:30 p.m. EDT on the same day, featuring CEO Dwight Egan, CFO Brian Brown, and General Counsel Reed Benson. Investors can access the live event via the company's website. For those unable to attend live, a recording will be made available later.

News Market Reaction – CODX

+0.66%

+0.66% Session move

In the trading session that priced this news, CODX gained 0.66%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SALT LAKE CITY, March 18, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth-quarter and full-year 2020 results on March 25, 2021, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. EDT to discuss its financial results with analysts and institutional investors. Management on the call will include CEO Dwight Egan, newly appointed CFO Brian Brown, and Reed Benson, General Counsel.

The call and webcast will be available via:

Webcast:	ir.codiagnostics.com on the Events & Webcasts page
Conference Call:	877-317-6789 (domestic) or 412-317-6789 (international)

If you are unable to participate during the live webcast, the call will be recorded and later made available on the Company's website.

About Co-Diagnostics, Inc.
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures, and markets a new, state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/co-diagnostics-inc-announces-fourth-quarter-and-full-year-2020-earnings-release-date-and-webcast-301249972.html

SOURCE Co-Diagnostics

FAQ

When will Co-Diagnostics release its fourth-quarter and full-year 2020 results?

Co-Diagnostics will release its financial results on March 25, 2021, after the market closes.

What time is the Co-Diagnostics conference call and webcast?

The conference call and webcast will be held on March 25, 2021, at 4:30 p.m. EDT.

Who will participate in the Co-Diagnostics call on March 25, 2021?

CEO Dwight Egan, CFO Brian Brown, and General Counsel Reed Benson will participate in the call.

How can I access the Co-Diagnostics conference call?

The conference call can be accessed via the company's website or by calling 877-317-6789 (domestic) or 412-317-6789 (international).